SSA retatrutide searches usually point to research-grade sourcing talk. Learn what retatrutide is, trial dosages, side effects, and when it may be approved.
SSA retatrutide is a search term that usually points to research-grade retatrutide sold by third-party suppliers, or to the abbreviation "SSA" used in online peptide communities. Retatrutide itself is an investigational drug from Eli Lilly that is not FDA-approved for any use, so no US pharmacy can legally dispense it. Everything below comes from published trial data and public regulatory information.
What Is Retatrutide?
Retatrutide (development code LY3437943) is a single peptide that activates three hormone receptors at once: GIP, GLP-1, and glucagon. That triple mechanism is what separates it from semaglutide, which targets GLP-1 only, and tirzepatide, which targets GIP and GLP-1.
Eli Lilly is studying retatrutide for obesity, type 2 diabetes, obstructive sleep apnea, and knee osteoarthritis. Retatrutide is an investigational drug, not an approved medication, and it has no approved human indication anywhere in the world.
In a Phase 2 obesity trial published in the New England Journal of Medicine, participants taking 12 mg weekly lost an average of 24.2% of body weight over 48 weeks. A separate Phase 2 trial in type 2 diabetes showed large reductions in A1c and body weight over 36 weeks.
What People Mean by "SSA Retatrutide"
In peptide forums and group-buy channels, "SSA" is often shorthand for a supplier or source. Searches for SSA retatrutide typically lead to vendor pages, price lists, and user reviews rather than clinical information.
Those listings deserve scrutiny. Retatrutide has never been approved, so there is no reference standard for a grey-market vial, and buyers cannot confirm identity, purity, or sterility before injection.
- Identity risk: the vial may contain a different peptide or a degraded fragment.
- Purity risk: leftover synthesis reagents and solvents are common in unregulated powders.
- Dose risk: mislabeled concentrations can cause accidental overdose.
A certificate of analysis from an unaccredited lab does not prove that a vial contains retatrutide or that it is safe to inject.
A smaller group of searchers uses "SSA" to mean the Social Security Administration. The SSA does not administer prescription drug coverage in the United States; Medicare, Medicaid, and private insurers handle that.
Retatrutide Dosage in Clinical Trials
Trial dosing has used weekly subcutaneous injection with slow escalation, a strategy designed to limit gastrointestinal effects. Doses studied range from 0.5 mg to 12 mg per week.
| Trial | Population | Doses studied | Duration | Key result |
|---|---|---|---|---|
| Phase 2 (obesity) | Adults with obesity, no diabetes | 1, 4, 8, 12 mg weekly | 48 weeks | Up to 24.2% mean weight loss at 12 mg |
| Phase 2 (type 2 diabetes) | Adults with type 2 diabetes | 0.5 to 12 mg weekly | 36 weeks | A1c reductions of roughly 2% at higher doses |
| Phase 3 TRIUMPH program | Obesity, diabetes, sleep apnea, knee OA | Escalation to 12 mg | Ongoing | Not yet reported |
Because Phase 3 results are still pending, no validated human dosing schedule exists for general use. Anyone researching retatrutide dosage outside a clinical trial is working from incomplete information.
Retatrutide Side Effects
The side effect profile looks similar to other incretin-based drugs, but with higher rates at the top doses. Gastrointestinal symptoms dominate the reports.
- Nausea, diarrhea, vomiting, and constipation, usually during dose escalation.
- Reduced appetite and early satiety, which are partly therapeutic effects.
- Modest increases in resting heart rate.
- Injection site reactions and, less commonly, gallbladder events.
Most reported retatrutide side effects are mild to moderate and improve as the body adjusts. A minority of trial participants stopped treatment because of them, and discontinuation rates rose with dose.
Long-term safety data remain limited. Anyone with a history of pancreatitis, gastroparesis, gallbladder disease, or medullary thyroid cancer should discuss risks with a healthcare professional before considering any GLP-1 class drug.
How Retatrutide Compares With Other Compounds
| Compound | Receptors | Approval status | Reported weight loss |
|---|---|---|---|
| Retatrutide | GIP, GLP-1, glucagon | Investigational | About 24% at 48 weeks (Phase 2, 12 mg) |
| Tirzepatide | GIP, GLP-1 | Approved (Zepbound) | About 21% at 72 weeks (15 mg) |
| Semaglutide | GLP-1 | Approved (Wegovy) | About 15% at 68 weeks (2.4 mg) |
| Cagrilintide | Amylin | Investigational | Studied mainly alongside semaglutide |
Cross-trial numbers are not head-to-head comparisons, so treat them as directional only. A true cagrilintide vs retatrutide vs tirzepatide comparison will not be possible until dedicated studies report results.
A direct aod 9604 vs retatrutide comparison is also limited, because AOD 9604 is a growth hormone fragment studied for lipolysis while retatrutide is a triple receptor agonist. The two compounds work through different pathways and have never been compared in a controlled trial.
When Will Retatrutide Be Available?
Eli Lilly has not announced an approval date. The Phase 3 TRIUMPH program is still running, and regulatory submission typically follows completion and analysis of those trials.
Retatrutide is not expected to be available by prescription in the United States until Phase 3 trials are complete and the FDA grants approval. Even then, insurance coverage and pricing will take additional time to settle.
Anyone asking when will retatrutide be available should follow Lilly's trial registries and FDA announcements rather than vendor timelines. Supplier pages that promise "in stock" retatrutide are selling an unapproved research chemical, not a finished drug.
Safety and Legal Takeaways
- Retatrutide is not FDA-approved for human use in the United States.
- Compounding pharmacies are not permitted to make copies of retatrutide, because there is no approved version and no FDA-listed shortage.
- Vials sold online as retatrutide are unregulated and may be mislabeled, underdosed, or contaminated.
- Approved alternatives such as tirzepatide and semaglutide exist for weight management and type 2 diabetes.
- Anyone considering a GLP-1 class medication should consult a licensed healthcare professional.
The clearest conclusion from the available evidence is simple: retatrutide looks promising in trials, but it is not a purchasable medicine, and no supplier abbreviation changes that.
Frequently Asked Questions
Is retatrutide FDA-approved?
No. Retatrutide is an investigational triple receptor agonist being developed by Eli Lilly, and it is not approved for any human use in the United States or elsewhere. Phase 3 trials in the TRIUMPH program are still ongoing, so no prescription version exists.
What does "SSA" mean in SSA retatrutide?
In peptide communities, SSA is typically shorthand for a supplier or source, and searches usually lead to unverified vendor listings rather than clinical data. SSA can also mean the Social Security Administration, which does not administer prescription drug coverage in the US.
When will retatrutide be available in the United States?
No approval date has been announced. Retatrutide cannot be sold by prescription until Phase 3 trials finish and the FDA reviews a marketing application, which typically takes additional time after trials end.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.